Compare Ross Stores, Inc. (ROST) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ross Stores, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Ross Stores, Inc. trades at $226 (market cap $72.05B), while Recursion Pharmaceuticals Inc trades at $4.02 (market cap $2.31B). The key difference: Ross Stores, Inc. is far larger — about 31.2× Recursion Pharmaceuticals Inc's market cap, and Ross Stores, Inc. pays a 0.79% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ross Stores, Inc. for 48 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| ROST | RXRX | |
|---|---|---|
Market Cap | $72.05B | $2.31B |
Volume | 1,674,861 | 40,478,768 |
Sector | Consumer Cyclical | Health |
52-Week High | $255.23 | $6.79 |
52-Week Low | $147.71 | $2.84 |
Typical Hold Time | 48 Days | 22 Days |
Enterprise Value | $72.50B | $1.83B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ross Stores (ROST) trades at $225.20, up 0.44% today, showing strong fundamental performance with consistent earnings beats and robust profitability metrics including 42.63% ROE and 10.85% net margin. The stock faces technical headwinds with a bearish signal from moving averages, trading near support at $224. Recent news highlights store expansion initiatives and strong closeout supply benefits as the company captures value-conscious shoppers amid competitive retail pressures.
ROST presents a compelling investment case with analyst consensus pointing to 22% upside to the $274.14 price target, supported by strong earnings momentum and expanding margins. Key risks include retail competition, cost pressures, and macroeconomic sensitivity, but the company's value-focused strategy and operational discipline position it well for sustained growth.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
